News
Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo Nordisk
Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company's share price.
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
StockStory.org on MSN4h
Why Is Hims & Hers Health (HIMS) Stock Soaring TodayWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the ...
Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. ("Hims & Hers") ( NYSE: HIMS) on behalf ...
Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press ...
A handful of prominent companies on Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades. Among the group is Hims & Hers (NYSE:HIMS) and Shell (NYSE:SHEL), ...
In its first-quarter 2025 investor letter, Carillon Scout Mid Cap Fund highlighted stocks such as Hims & Hers Health, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback